{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T17:40:38Z","timestamp":1781977238577,"version":"3.54.5"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2,1]]},"DOI":"10.1093\/cid\/cit697","type":"journal-article","created":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T00:55:40Z","timestamp":1382403340000},"page":"423-431","source":"Crossref","is-referenced-by-count":101,"title":["Resistance to HIV Integrase Strand Transfer Inhibitors Among Clinical Specimens in the United States, 2009\u20132012"],"prefix":"10.1093","volume":"58","author":[{"given":"Christopher B.","family":"Hurt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Eron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,10,21]]},"reference":[{"key":"key\n\t\t\t\t20170522111817_CIT697C1","article-title":"Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2009"},{"key":"key\n\t\t\t\t20170522111817_CIT697C2","article-title":"Drug approval package: Isentress (raltegravir) NDA #022145","author":"United States Food and Drug Administration"},{"key":"key\n\t\t\t\t20170522111817_CIT697C3","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1086\/650002","article-title":"Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials","volume":"50","author":"Steigbigel","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522111817_CIT697C4","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/cid\/cir510","article-title":"Long-term treatment with raltegravir or efavirenz combined with tenofovir\/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK","volume":"53","author":"Rockstroh","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522111817_CIT697C5","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"379","author":"DeJesus","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170522111817_CIT697C6","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170522111817_CIT697C7","article-title":"Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2013"},{"key":"key\n\t\t\t\t20170522111817_CIT697C8","article-title":"Drug approval package: Stribild (cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate) NDA #203100","author":"United States Food and Drug Administration"},{"key":"key\n\t\t\t\t20170522111817_CIT697C9","article-title":"Drug approval package: Tivicay (dolutegravir) NDA #204790","author":"United States Food and Drug Administration"},{"key":"key\n\t\t\t\t20170522111817_CIT697C10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1473-3099(13)70093-8","article-title":"Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials","volume":"13","author":"Eron","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20170522111817_CIT697C11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","article-title":"Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1 infected patients: final five-year results from STARTMRK","volume":"63","author":"Rockstroh","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170522111817_CIT697C12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/QAI.0b013e3181e9a87a","article-title":"Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness","volume":"55","author":"Hu","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170522111817_CIT697C13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/QCO.0b013e32835a1de7","article-title":"Emerging patterns and implications of HIV-1 integrase inhibitor resistance","volume":"25","author":"Geretti","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"key\n\t\t\t\t20170522111817_CIT697C14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/jac\/dkp014","article-title":"Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients","volume":"63","author":"Malet","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170522111817_CIT697C15","article-title":"Emergent drug resistance from the HIV-1 phase 3 elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate studies through week 96","author":"White","year":"2013"},{"key":"key\n\t\t\t\t20170522111817_CIT697C16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522111817_CIT697C17","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1128\/AAC.00204-13","article-title":"Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir","volume":"57","author":"Huang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522111817_CIT697C18","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/QAD.0b013e3283473599","article-title":"Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143","volume":"25","author":"M\u00e9tifiot","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170522111817_CIT697C19","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study","volume":"207","author":"Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522111817_CIT697C20","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.15.6.18112","article-title":"Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3","author":"Nichols","year":"2012"},{"key":"key\n\t\t\t\t20170522111817_CIT697C21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/QAI.0b013e3181c42ea4","article-title":"Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy","volume":"54","author":"Hatano","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170522111817_CIT697C22","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/JVI.06591-11","article-title":"Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir","volume":"86","author":"Quashie","year":"2012","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20170522111817_CIT697C23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-4690-10-22","article-title":"Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure","volume":"10","author":"Mespl\u00e8de","year":"2013","journal-title":"Retrovirology"},{"key":"key\n\t\t\t\t20170522111817_CIT697C24","article-title":"Dolutegravir vs raltegravir in ART-experienced, integrase-naive subjects: 24-week interim results from SAILING (ING111762)","author":"Pozniak","year":"2013"},{"key":"key\n\t\t\t\t20170522111817_CIT697C25","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1093\/jac\/dkr389","article-title":"The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype","volume":"66","author":"Malet","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170522111817_CIT697C26","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/infdis\/jir025","article-title":"HIV-1 integrase inhibitor resistance and its clinical implications","volume":"203","author":"Blanco","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522111817_CIT697C27","doi-asserted-by":"crossref","first-page":"11440","DOI":"10.1128\/JVI.01168-09","article-title":"Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways","volume":"83","author":"Fransen","year":"2009","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20170522111817_CIT697C28","first-page":"6","article-title":"Update of the drug resistance mutations in HIV-1: March 2013","volume":"21","author":"Johnson","year":"2013","journal-title":"Top Antivir Med"},{"key":"key\n\t\t\t\t20170522111817_CIT697C29","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522111817_CIT697C30","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update","volume":"4","author":"Bennett","year":"2009","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170522111817_CIT697C31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/QAI.0b013e31826bfd02","article-title":"The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults","volume":"61","author":"Underwood","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170522111817_CIT697C32","article-title":"Rapid increase in the frequency of wild-type HIV-1 drug resistance reports among ART-experienced patients: UK","author":"Dolling","year":"2013"},{"key":"key\n\t\t\t\t20170522111817_CIT697C33","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S1473-3099(11)70196-7","article-title":"Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial","volume":"11","author":"Eron","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20170522111817_CIT697C34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3851\/IMP1749","article-title":"Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient","volume":"16","author":"Boyd","year":"2011","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170522111817_CIT697C35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3851\/IMP1748","article-title":"Transmission of integrase strand-transfer inhibitor, multidrug resistant HIV-1: case report and natural history of response to raltegravir-containing antiretroviral therapy","volume":"16","author":"Young","year":"2011","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170522111817_CIT697C36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3851\/IMP1750","article-title":"Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule","volume":"16","author":"Hurt","year":"2011","journal-title":"Antivir Ther"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/58\/3\/423\/17351655\/cit697.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T18:42:30Z","timestamp":1503427350000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/cit697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,21]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,10,21]]},"published-print":{"date-parts":[[2014,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cit697","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10,21]]}}}